RT Journal Article
SR Electronic
T1 Differential antibody production by symptomatology in SARS-CoV-2 convalescent individuals
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.09.22270718
DO 10.1101/2022.02.09.22270718
A1 Saraf, Sharada
A1 Zhu, Xianming
A1 Shrestha, Ruchee
A1 Bonny, Tania S.
A1 Baker, Owen R.
A1 Beck, Evan J.
A1 Fernandez, Reinaldo E.
A1 Eby, Yolanda
A1 Akinde, Olivia
A1 Ruff, Jessica E.
A1 Caturegli, Patrizio
A1 Redd, Andrew D.
A1 Bloch, Evan M.
A1 Quinn, Thomas C.
A1 Tobian, Aaron AR
A1 Laeyendecker, Oliver
YR 2022
UL http://medrxiv.org/content/early/2022/02/10/2022.02.09.22270718.abstract
AB The association between COVID-19 symptoms and antibody responses against SARS-CoV-2 is poorly characterized. We analyzed antibody levels in individuals with known SARS-CoV-2 infection to identify potential antibody-symptom associations. Convalescent plasma from 216 SARS-CoV-2 RNA+ individuals with symptomatology information were tested for the presence of IgG to the spike S1 subunit (Euroimmun ELISA), IgG to receptor binding domain (RBD, CoronaCHEK rapid test), and for IgG, IgA, and IgM to nucleocapsid (N, Bio-Rad ELISA). Logistic regression was used to estimate the odds of having a COVID-19 symptom from the antibody response, adjusting for sex and age. Cough strongly associated with antibodies against S1 (adjusted odds ratio [aOR]= 5.33; 95% CI from 1.51 to 18.86) and RBD (aOR=4.36; CI 1.49, 12.78). In contrast, sore throat significantly associated with the absence of antibodies to S1 and N (aOR=0.25; CI 0.08, 0.80 and aOR=0.31; 0.11, 0.91). Similarly, lack of symptoms associated with the absence of antibodies to N and RBD (aOR=0.16; CI 0.03, 0.97 and aOR=0.16; CI 0.03, 1.01). Cough appeared to be correlated with a seropositive result, suggesting that SARS-CoV-2 infected individuals exhibiting lower respiratory symptoms generate a robust antibody response. Conversely, those without symptoms or limited to a sore throat while infected with SARS-CoV-2 were likely to lack a detectable antibody response. These findings strongly support the notion that severity of infection correlates with robust antibody response.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04373460 Funding StatementThis work was supported in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID) (OL, ADR, TCQ), as well as extramural support from NIAID (R01AI120938, R01AI120938S1 and R01AI128779 to AART funders had no role in study design, data analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study used stored samples and data from studies that were approved by The Johns Hopkins University School of Medicine Institutional Review Board (IRB00250798). All study participants provided written informed consent and were de-identified prior to laboratory testing.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available as a supplemental file.